Merck KGaA to Acquire Silence Therapeutics

Company Merck KGaA; Silence Therapeutics Event Type Acquisition (all-cash) Modality siRNA (mRNAi GOLD platform), subcutaneous quarterly dosing Asset Divesiran Target TMPRSS6 (hepcidin pathway) Disease Area Polycythemia vera Summary Merck KGaA agreed to acquire Silence Therapeutics in an all-cash transaction valued at approximately $1.3 billion in…